News Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 17/04/2026 HKT			Pre-market 20:50:19
234.54 ^USD	-1.73%		235.00	+0.20%

04:00pm	Moberg Pharma proposes Lars Johansson as new Chairman	FW
04-16	MeiraGTx Acquires Bota-vec From Johnson & Johnson; Reports Positive Three-Year Early-Stage Data From AAV-hAQP1 Program in Xerostomia	MT

All News

04:00pm	Moberg Pharma proposes Lars Johansson as new Chairman	FW
04-17	Johnson & Johnson : First Quarter 2026 2026 First-Quarter Earnings Transcript	PU
04-17	Johnson & Johnson : 1Q26 Other Financial Disclosures	PU
04-16	MeiraGTx Acquires Bota-vec From Johnson & Johnson; Reports Positive Three-Year Early-Stage Data From AAV-hAQP1 Program in Xerostomia	MT
04-16	US FDA's accelerated approval for drugs needs more transparency, says research firm	RE
04-16	Daiwa Securities Adjusts PT on Johnson & Johnson to $246 From $237, Maintains Outperform Rating	MT
04-16	Argus Research Adjusts PT on Johnson & Johnson to $275 From $240, Maintains Buy Rating	MT
04-16	Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference	BU
04-16	Argus Raises Price Target on Johnson & Johnson to $275 From $240	MT
04-16	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
04-16	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
04-15	BofA Securities Raises Price Target on Johnson & Johnson to $254 From $253, Maintains Neutral Rating	MT
04-15	Johnson & Johnson Q1 Reinforces Growth Outlook on New Product Cycle, Morgan Stanley Says	MT
04-15	Johnson & Johnson Highlights Pipeline Catalysts, Reaffirms Growth Outlook After Q1 Beat, RBC Says	MT
04-15	Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal	RE
04-15	RBC Raises Price Target on Johnson & Johnson to $265 From $255, Keeps Outperform Rating	MT
04-15	Morgan Stanley Lifts Price Target on Johnson & Johnson to $283 From $267, Maintains Overweight Rating	MT
04-15	Stifel Adjusts Price Target on Johnson & Johnson to $250 From $220, Maintains Hold Rating	MT
04-15	Barclays Adjusts Price Target on Johnson & Johnson to $255 From $234, Maintains Equalweight Rating	MT
04-15	Goldman Sachs Adjusts Price Target on Johnson & Johnson to $275 From $265, Maintains Buy Rating	MT
04-15	Wells Fargo Adjusts Price Target on Johnson & Johnson to $263 From $240, Maintains Overweight Rating	MT
04-15	Bernstein Adjusts Price Target on Johnson & Johnson to $251 From $225, Maintains Market Perform Rating	MT
04-15	JPMorgan Adjusts Price Target on Johnson & Johnson to $260 From $250, Maintains Neutral Rating	MT
04-15	Leerink Partners Adjusts PT on Johnson & Johnson to $252 From $232, Maintains Market Perform Rating	MT
04-15	Raymond James Adjusts PT on Johnson & Johnson to $258 From $237, Maintains Outperform Rating	MT